NASDAQ | TSX: ACB
• Believed to be the largest
shipment of medical cannabis to Israel to-date
• Aurora continues to advance strategic
leadership in the global cannabinoid industry
EDMONTON, AB, Jan. 4, 2022 /CNW/ - Aurora Cannabis Inc. (the
"Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian
company defining the future of cannabinoids worldwide, announced
today the delivery of a cannabis shipment worth approximately
C$10 million - the company's largest
ever shipment to Israel, and what
is believed to be the largest export of medical Cannabis into the
Israeli market. Delivered in December, the shipment will be
recognized as revenue in Aurora's FY22 Q2 period.
The sale builds on the Company's growing presence in
Israel, a key market as Aurora
continues to strengthen its international medical business. As the
leading Canadian licensed producer (LP) in global medical cannabis
by revenue, Aurora has strategically focused on international
expansion to bolster its diversified business portfolio. The
Company also recently entered into a joint venture in The Netherlands to participate in the
Controlled Cannabis Supply Chain Experiment, an adult-use pilot
program.
"It's an exciting time for the global cannabis industry, as
we're seeing growing acceptance and thoughtful regulation of both
medical and adult-use cannabis across Europe and in key markets like Israel," says Miguel
Martin, Chief Executive Officer of Aurora. "With strong
local relationships, as well as support from our patients and
consumers, we look forward to continuing to expand our
international business to complement our total cannabis
portfolio."
About Aurora:
Aurora is a global leader in the cannabis industry, serving both
the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis dedicated to helping people improve their lives.
The Company's brand portfolio includes Aurora, Aurora Drift, San
Rafael '71, Daily Special, MedReleaf, CanniMed, Pedanios, Whistler,
Reliva and KG7 CBD. Driven by science and innovation,
and with a focus on high-quality cannabis products, Aurora's brands
continue to break through as industry leaders in the medical,
performance, wellness and adult recreational markets wherever they
are launched. Learn more at www.auroramj.com and follow us on
Twitter and LinkedIn.
Aurora's common shares trade on the TSX and NASDAQ under the symbol
"ACB" and is a constituent of the S&P/TSX Composite Index.
Forward-looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in
this news release include, but are not limited to, statements
regarding the Company's continued supply of medical cannabis
to Israel and the continued
expansion of the Company's international medical business.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news
release have been developed based on assumptions
management considers to be reasonable. Material factors
or assumptions involved in developing forward-looking statements
include, without limitation, publicly available information from
governmental sources as well as from market research and industry
analysis and on assumptions based on data and knowledge of this
industry which the Company believes to be reasonable.
Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be
relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's
estimates of consumer demand in Canada and in jurisdictions where the Company
exports, expectations of future results and expenses, the risk
of successful integration of acquired business and operations,
management's estimation that SG&A will grow only in proportion
of revenue growth, the ability to expand and maintain distribution
capabilities, the impact of competition, the general impact of
financial market conditions, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, including the current outbreak of
COVID-19, and other risks, uncertainties and factors set out
under the heading "Risk Factors" in the Company's annual
information form dated September 27,
2021 (the "AIF") and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR
at www.sedar.com and filed with and available on the
SEC's website at www.sec.gov. The Company cautions
that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely
affect its results. Readers are urged to consider the risks,
uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-delivers-10-million-shipment-of-medical-cannabis-to-israel-301453278.html
SOURCE Aurora Cannabis Inc.